Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, December 2005, p. 5176-5178, Vol. 49, No. 12
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.12.5176-5178.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Kwan Soo Ko,1,2,
Jae-Hoon Song,1,2*
Mi Young Lee,2
Sulhee Park,2
Kyong Ran Peck,1
Nam Yong Lee,3
Choon-Kwan Kim,4
Hyuck Lee,5
Shin-Woo Kim,6
Hyun-Ha Chang,6
Yeon-Sook Kim,7
Sook-In Jung,8
Jun Seong Son,9
Joon-Sup Yeom,10
Hyun Kyun Ki,11 and
Gun-Jo Woo12
Division of Infectious Diseases,1 Department of Laboratory Medicine, Samsung Medical Center, Seoul,3 Kangbuk Samsung Hospital, Seoul,10 Sungkyunkwan University School of Medicine, Asian-Pacific Research Foundation for Infectious Diseases (ARFID), Seoul,2 Seoul Veterans Hospital, Seoul,4 Dong-A University Hospital, Busan,5 Kyungpook National University Hospital, Daegu,6 Chungnam National University Hospital, Daejeon,7 Chonnam National University Medical School, Gwangju,8 Chungbuk National University Hospital, Chungju,9 Konkuk University Hospital, Seoul,11 Division of Food Microbiology, Korean Food & Drug Administration, Seoul, Korea,12
Received 14 July 2005/ Returned for modification 19 August 2005/ Accepted 20 September 2005
We tested the in vitro susceptibilities of 603 enterococcal isolates from eight tertiary-care hospitals in Korea. The quinupristin-dalfopristin resistance rate in Enterococcus faecium was very high (25 isolates, 10.0%). It was suggested that both clonal spread and the sporadic emergence of quinupristin-dalfopristin-resistant isolates may explain the high prevalence of quinupristin-dalfopristin resistance in Korea.
W.S.O and K.S.K. contributed equally as joint first authors.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |